NGOs 
Business and Human Rights: Interview with John Ruggie(1)
In July 2011, the United Nations Human Rights Council endorsed a set of principles designed to address human rights abuses by business. In an interview, the man who led development of those principles – Harvard professor John Ruggie – discusses their implications and explains why he thinks the newly-coined term “human rights due diligence” has already become a permanent entry in the lexicon of international business.
Full Story»Panera Cares: An Experiment in Corporate Responsibility
Columnist Gael O’Brien discusses an innovative corporate responsibility initiative launched by Panera Bread, the national cafe-bakery company. “Panera Cares” has opened community cafes in three cities – Clayton, Missouri; Dearborn, Michigan and Portland, Oregon – based on a pay-what-you-can model where those who can pay more do in order to cover the cost of others.
UN Council Endorses Principles on Business and Human Rights
The UN’s endorsement of the Guiding Principles on Business and Human Rights marks not just a successful end to the mandate of UN Special Representative John Ruggie. It also signals a new beginning for business and human rights as companies around the world begin to implement the principles to ensure respect for human rights in all their operations.
Following Kimberly-Clark’s Agreements on Wood Sourcing and Recycling
In August 2009, Kimberly-Clark, the paper giant behind the Kleenex, Cottonelle and Scott brands and the largest manufacturer of tissue products in the world, gave in to pressure from Greenpeace and other environmental groups to clean up its act in regard to how it sources its wood fiber and how much recycled content it includes in its products.
More in this category
- Opinion: Traditional Philanthropy Gives Way to a New Power
- Opinion: When Women Rule the C-Suite
- Trying to Break the Sweatshop Business Model
- Export Credit Agencies Urged to Strengthen Anti-Bribery Rules
- Shareholders Press for Political Spending Disclosure
- GlaxoSmithKline, Merck, Novartis Top Access to Medicine Report

